Drug Type Antisense oligonucleotides |
Synonyms C-myb Antisense (AS) Oligonucleotides (ODNs)(Abramson Cancer Center of the University of Pennsylvania), C-myb Antisense Oligodeoxynucleotide(Abramson Cancer Center of the University of Pennsylvania) |
Target |
Mechanism c-myb inhibitors(Transcriptional activator Myb inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 2 | US | 30 Jun 1993 | |
Hematologic Neoplasms | Phase 1 | US | 26 Sep 2016 |
Not Applicable | - | - | Combined antisense oligonucleotides (AS-oligos) | jxfdvdhdxz(xgvsbmmvcu) = xnhnjwnifj qrctlmigpg (gbfcexhhsm ) View more | - | 01 May 2006 | |
Random oligonucleotides (Ran oligos) | jxfdvdhdxz(xgvsbmmvcu) = wrpzuhfxon qrctlmigpg (gbfcexhhsm ) View more |